CHEERLEADER Study: Understanding characteristics, treatment patterns, clinical outcomes, healthcare resource utilization, and costs among patients with de novo muscle-invasive bladder cancer in Canada
Summary
Client: IQVIA Solutions Canada Inc.
Project ID: P2023-189/ 2025 0980 005 000
Research Question/Objectives: Bladder cancer ranks as the fifth most common cancer in Canada. Muscle-invasive bladder cancer (MIBC), a more aggressive form, accounts for approximately 20-25% of cases and 5-11% of patients have locally advanced or metastatic disease at diagnosis (Hepp et al., 2021). Standard treatments for MIBC include neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy or bladder preservation with chemoradiotherapy. More than 30% of patients experience a recurrence after therapy (Lopez-Beltran et al., 2024, Brown et al., 2006). The retrospective CHEERLEADER study will analyse administrative data from patients with de novo (primary) MIBC in Ontario to understand treatment patterns, outcomes, and costs. To our knowledge, this will be the most comprehensive and up-to-date population-based study in Canada.
Objectives:
Primary objective:
- To estimate overall survival (OS) from initiation of treatment to death from any cause.
Secondary objectives:
- To describe baseline demographic and clinical characteristics.
- To characterize current treatment patterns for patients with de novo MIBC.
- To describe healthcare resource utilization (HCRU) and associated healthcare costs.
Status: In progress